



Sheet 1 of 4

FORM PTO-1419
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 02-24

Serial No.
10/691,923

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAY 04 2005 (use several sheets if necessary)

Applicant(s):

Kevin M. Klucher, Pallavur V.
Sivakumar, Wayne R. Kindsvogel,
Katherine E. Henderson

Filing Date: October 23, 2003 Group: 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FH	A1 2003/0104416	06/05/03	Sheppard et al.	435	6	
	A2 2004/0029228	02/12/04	Presnell et al.	435	69.1	
	A3 2002/0039763	04/04/02	Sheppard et al.	435	69.1	
	A4 2004/0138122	07/15/04	Klucher et al.	514	12	
	A5 5,206,344	04/27/93	Katre et al.	530	351	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FH	A6 03/066002	08/14/03	WIPO			
	A7 02/086087	10/31/02	WIPO			
	A8 03/089603	10/30/03	WIPO			
	A9 02/20569	03/14/02	WIPO			
	A10 02/092762	11/21/02	WIPO			
	A11 0 032 134	07/15/81	EP			
	A12 04/037995	05/06/04	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

FH	A13	Kotenko et al., "IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex," <i>Nature Immunology</i> 4(1):69-77, 2003.
	A14	Sheppard et al., "IL-28, IL-29 and their class II cytokine receptor IL-28R," <i>Nature Immunology</i> 4(1):63-68, 2003.
	A15	Langer et al., "The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions," <i>Cytokine and Growth Factor Reviews</i> 15:33-48, 2004.
	A16	Donnelly et al., "The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain," <i>J. Leukocyte Biol.</i> 76:314-321, 2004.
	A17	Dumoutier et al., "Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-λ1," <i>J. Biochem.</i> 279(31):32269-32274, 2004.
	A18	University Calif. Santa Cruz Genome Browser – Chromosome 19, April 20, 2001.

Examiner

Fiona Hwang

Date considered

1/6/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 149
(REV 2-32)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

O I P E
MAY 03 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use several sheets if necessary)

O I P E
MAY 04 2003

File No. 02-24

Serial No.
10/691,923

Applicant(s):

Kevin M. Klucher, Pallavur V.
Sivakumar, Wayne R. Kindsvogel,
Katherine E. HendersonFiling Date:
October 23, 2003 Group: 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
------------------	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
------------------	-----------------	------	---------	-------	----------	----------------------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

FH	A19		University Calif. Santa Cruz Genome Browser Database – August 6, 2001, Accession No. C19001210.
	A20		University Calif. Santa Cruz Genome Browser Database – August 6, 2001, Accession No. C19001212.
	A21		University Calif. Santa Cruz Genome Browser Database – August 6, 2001, Accession No. C19001213.
	A22		University Calif. Santa Cruz Genome Browser Database – December 22, 2001, Accession No. C19001260.
	A23		University Calif. Santa Cruz Genome Browser Database – December 22, 2001, Accession No. C19001256.
	A24		University Calif. Santa Cruz Genome Browser Database – December 22, 2001, Accession No. C19001257.
	A25		Ensembl Contig. View Sanger Institute – April 19, 2001, Accession No. AC011445.
	A26		Ensembl Contig. View Sanger Institute – April 18, 2000, Accession No. AC018477.
	A27		Adams et al., "3,400 expressed sequence tags identify diversity of transcripts from human brain," <i>Nat. Genet.</i> 4:256-267, 1993.
	A28		GenBank Submission XP-002202436, October 12, 2000.
	A29		GenBank Submission XP-002202437, December 12, 1999.
	A30		Kindsvogel et al., "Novel Interferon-Like Cytokines not Recognized by the Type I Interferon Receptor," <i>J. Interferon Cytokine Res.</i> 22(1):S-48, 2002.
	A31		Adams et al., Accession No. T07139, 1993.
	A32		DOE Joint Genome Institute Stanford Human Genome Center, Accession No. AC011445, 1999.
✓	A33		Muzney et al., Accession No. AC007458, 1999.

Examiner	Date considered
<i>John H</i>	1/9/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 02-24	Serial No. 10/691,923		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant(s): Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Katherine E. Henderson			
				Filing Date: October 23, 2003	Group: 1646 7		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)							
<i>F H</i>	A34		University of California Santa Cruz database using Softberry, Inc. gene prediction software, Accession No. CI9001084, 2001.				
	A35		Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," <i>Nature Genetics</i> , 21:440-443, 1999.				
	A36		Korba et al., "A cell culture assay for compounds which inhibit hepatitis B virus replication," <i>Antiviral Research</i> 15:217-228, 1991.				
	A37		Brack et al., "Molecular analysis of the human interferon- α gene family," <i>Gene</i> 15:379-394, 1981.				
	A38		Francis et al., "PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques," <i>International Journal of Hematology</i> , 68(1):1-18, 1998.				
	A39		Rajarathnam et al., "Disulfide Bridges in Interleukin-8 Probed Using Non-Natural Disulfide Analogues: dissociation of Roles in Structure from Function," <i>Biochemistry</i> 38:7653-7658, 1999.				
	A40		Luxon et al., "Pegylated Interferons for the Treatment of Chronic Hepatitis C Infection," <i>Clinical Therapeutics</i> 24(9):1363-1383, 2002.				
	A41		Kozlowski et al., "Improvements in protein OEGylation: pegylated interferons for treatment of hepatitis C," <i>Journal of Controlled Release</i> 72:217-224, 2001.				
	A42		Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site," <i>Bio/Technology</i> 8(4):343-346, 1990.				
<i>V</i>	A43		Pettit et al., "Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling," <i>J. Biochem</i> 272(4):2312-2318, 1997.				
Examiner <i>F H</i>			Date considered <i>11/9/06</i>				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

